# Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)

> **NCT06100900** · PHASE1 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** BCX10013

## Key facts

- **NCT ID:** NCT06100900
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-24
- **Primary completion:** 2024-12-11
- **Final completion:** 2024-12-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06100900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06100900, "Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06100900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*